Login / Signup

Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.

Nadine G RouphaelAngela R BrancheDavid J DiemertAnn R FalseyCecilia LosadaLindsey R BadenSharon E FreyJennifer A WhitakerSusan J LittleSatoshi KamidaniEmmanuel B WalterRichard M NovakRichard RuppLisa A JacksonTara M BabuAngelica C KottkampAnne F LuetkemeyerLilly C ImmergluckRachel M PrestiMartín BäckerPatricia L WinokurSiham M MahgoubPaul A GoepfertDahlene N FuscoRobert L AtmarChristine M PosavadAntonia NetzlDerek J SmithKalyani TeluJinjian MuLisa J McQuarrieMat MakowskiMamodikoe K MakheneSonja CrandonDavid C MontefioriPaul C RobertsJohn H Beigel
Published in: The Journal of infectious diseases (2023)
We compared the serologic responses of one versus two doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A two-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.
Keyphrases
  • sars cov
  • coronavirus disease